GW Pharma Phase III Epidiolex Trial Data Summary

GW Pharma Phase III Epidiolex Trial Data Summary The passage provides detailed clinical trial results for Epidiolex but contains no references to influential political actors, financial misconduct, or intelligence agencies. It offers no actionable investigative leads beyond standard pharmaceutical reporting. Key insights: Phase III trial design and endpoints for Lennox‑Gastaut syndrome (LGS) and Dravet syndrome.; Epidiolex showed statistically significant seizure reductions versus placebo.; Adverse event profile and one unrelated death reported.